Compare American Superconductor Corporation (AMSC) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs BioNano Genomics Inc — how do they compare? American Superconductor Corporation trades at $32.32 (market cap $1.56B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: American Superconductor Corporation is far larger — about 114.2× BioNano Genomics Inc's market cap, and American Superconductor Corporation is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| AMSC | BNGO | |
|---|---|---|
Market Cap | $1.56B | $13.66M |
Sector | Technology | Health |
52-Week High | $66.68 | $4.92 |
52-Week Low | $25.95 | $1.06 |
Enterprise Value | $1.42B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $32.28, up 4.16% today, but faces a bearish technical outlook with 14 sell signals versus 3 buys. The company reported strong revenue growth with Q1 2026 sales up 30% to $94.1M (Zacks, Aug 7, 2026) and a record backlog over $400M, though Q2 earnings missed estimates amid margin pressure. Net income margin improved dramatically to 42.56% in 2026 from 2.7% in 2025, but cash flow turned negative with a $60M net outflow in 2026.
The stock presents a mixed opportunity: robust order growth and expanding margins support upside, but high EV/EBITDA (65.73) and technical weakness pose risks. Analyst consensus is bullish (53% Buy), yet investors should watch execution on backlog conversion and margin sustainability amid competitive and cost pressures.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
